(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 6 May 2004 (06.05.2004)

PCT

(10) International Publication Number WO 2004/037261 A1

A61K 31/506, (51) International Patent Classification7:

45/06, A61P 9/12

(21) International Application Number:

PCT/IB2003/004671

(22) International Filing Date: 20 October 2003 (20.10.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/421,318

25 October 2002 (25.10.2002) US

(71) Applicant (for all designated States except US): THE ADMINISTRATORS OF THE TULANE EDUCA-TIONAL FUND [US/US]; 1430 Tulane Avenue, SL-13, New Orleans, LA 70112 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LASKY, Joseph,

Alexander [US/US]; 1127 Philip Street, New Orleans, LA 70130 (US).

(74) Agents: HOXIE, Thomas et al.; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.


(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF N-'5-'4-(4-METHYLPIPERAZIOMETHYL)-BENZOYLAMIDO!-2-METHYLPHENYL!-4-(3-PYRIDYL)2-PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY HYPERTENSION



(57) Abstract: The present invention pertains the use of 4-(4-methylpiperazin-1-ylmethyl)-N[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of pulmonary hypertension.